12:46 PM EDT, 06/28/2024 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) plans to co-market Zydus Lifesciences' Pertuzumab biosimilar to treat breast cancer patients in India.

Zydus will market the product under the Sigrima brand name while Dr. Reddy's will sell it as Womab, the companies said Friday.

Dr. Reddy's will make an undisclosed upfront payment for the license and make additional payments as certain milestones are met.

Price: 76.44, Change: +1.04, Percent Change: +1.38